Key points are not available for this paper at this time.
Since the 2012 fungal meningitis outbreak caused by a compounded drug that had been prepared under inappropriate conditions, the FDA’s experience in monitoring pharmacy compounding has demonstrated the need for further improvement in compounding practices.
Woodcock et al. (Thu,) studied this question.